Zagociguat is under clinical development by Cyclerion Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zagociguat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zagociguat (CY-6463, IW-6463) is under development for the treatment of schizophrenia, mitochondrial encephalomyopathy, cognitive impairment associated with schizophrenia, lactic acidosis, central nervous system indications such as neuroinflammation, vascular dementia and Alzheimer’s disease. The drug candidate is administered by oral route. It targets soluble guanylate cyclase (sGC). It was under devlopment for the treatment of stroke-like episodes (MELAS).
Cyclerion Therapeutics overview
Cyclerion Therapeutics (Cyclerion), is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of mitochondrial diseases, including MELAS. It also discovers and develops soluble guanylate cyclase (sGC) stimulators. Cyclerion’s pipeline products include CY6463, for the treatment of MELAS; cognitive impairment associated with Schizophrenia (CIAS); and Alzheimer’s disease with vascular pathology (ADv); CY3018, a sGC stimulator, for the treatment of central nervous system related disorders. Cyclerion Therapeutics is headquartered in Cambridge, Massachusetts, the United States.
For a complete picture of Zagociguat’s drug-specific PTSR and LoA scores, buy the report here.